

Frequently used Codes for HEDIS® measures

CPT II and ICD 10 codes make it easier to track quality of care. The codes also simplify how quality performance measures are reported and eliminate the need for chart abstraction. Providers and hospitals can use these codes to report specific services that contribute to positive health outcomes and high-quality care.

Why use CPT II and diagnosis codes?

- Supply more accurate medical data and decrease requests for members' record to review
- Identify and close gaps in care more accurately and quickly – this drives HEDIS®
- Supports a proactive approach to addressing clinical care opportunities

Listed are HEDIS® measures and applicable codes.

HEDIS Measure	Codes
Controlling Blood Pressure (CBP)	<p>3074F – Systolic BP < 130mmHg 3075F – Systolic BP 130 – 139mmHg 3077F – Systolic BP ≥ 140mmHg 3078F – Diastolic BP < 80mmHg 3079F – Diastolic BP 80 - 89mmHg 3080F – Diastolic BP ≥ 90mmHg</p>
Breast Cancer Screening (BCS-E)	<p>77061 – provider performs unilateral digital tomosynthesis for diagnostic 77062 – provider performs bilateral digital tomosynthesis for diagnostic</p> <p>Exclusions Z90.11 – Absence of Right Breast Z90.12 – Absence of Left Breast Z90.13 – Absence of both Breasts</p>
Colon Cancer Screening (COL-E)	<p>82270, 82274 – FOBT HCPCS G0328 – FOBT 81528 – Cologuard (sDNA FIT)</p> <p>Exclusions Z85.038 – History of other malignant neoplasm of large intestine Z85.048 – History of other malignant neoplasm of rectum, rectosigmoid junction, and anus C18.0 – C18.9, C19, C20, C21.2, C21.8 – Active colon cancer C78.5 – Secondary malignant neoplasm of large intestine and rectum</p>



Arkansas
BlueCross BlueShield

An Independent Licensee of the Blue Cross and Blue Shield Association

HEDIS Measure	CPTII Codes / ICD Codes														
Eye Exam for Patients with Diabetes (EED)	<p>2022F – Dilated retinal exam interpreted by an eye care professional documented/ reviewed, with evidence of retinopathy</p> <p>2023F – Dilated retinal eye exam interpreted by an eye care professional documented/ reviewed, without evidence of retinopathy</p> <p>3072F – Low risk for retinopathy (no evidence of retinopathy in the prior year)</p>														
Glycemic Status Assessment for Patients with Diabetes (GSD)	<p>3044F – A1c < 7.0%</p> <p>3051F – A1c 7.0% - 7.9%</p> <p>3052F – A1c 8.0% - 9.0%</p> <p>3046F – A1c > 9.0%</p>														
Osteoporosis Management in Women who had a Fracture (OMW)	<p>J0897 – Injection, Denosumab 1mg</p> <p>J1740 – Injection, Ibandronate sodium, 1mg</p> <p>J3489 – injection, Zoledronic acid, 1mg</p>														
Statin Therapy for Patients with Cardiovascular Disease (SPC)	<table border="1"> <thead> <tr> <th colspan="2" data-bbox="506 871 1513 919">Exclusions</th> </tr> </thead> <tbody> <tr> <td data-bbox="506 919 771 961">Myalgia</td> <td data-bbox="771 919 1513 961">M79.10 – M479.12, M79.18</td> </tr> <tr> <td data-bbox="506 961 771 1138">Myositis</td> <td data-bbox="771 961 1513 1138">M60.80 – M60.819, M60.821 – M60.829, M60.831 – M60.839, M60.841 – M60.849, M60.851 – M60.859, M60.861 – M60.869, M60.871 – M60.88, M60.89, M60.9</td> </tr> <tr> <td data-bbox="506 1138 771 1180">Myopathy</td> <td data-bbox="771 1138 1513 1180">G72.0, G72.2, G72.9</td> </tr> <tr> <td data-bbox="506 1180 771 1222">Rhabdomyolysis</td> <td data-bbox="771 1180 1513 1222">M62.82</td> </tr> <tr> <td data-bbox="506 1222 771 1306">Cirrhosis</td> <td data-bbox="771 1222 1513 1306">K70.30, K70.31, K71.7, K74.3 -K74.5, K74.60, K74.69, P78.81</td> </tr> <tr> <td data-bbox="506 1306 771 1348">ESRD</td> <td data-bbox="771 1306 1513 1348">N18.5, N18.6, Z99.2</td> </tr> </tbody> </table>	Exclusions		Myalgia	M79.10 – M479.12, M79.18	Myositis	M60.80 – M60.819, M60.821 – M60.829, M60.831 – M60.839, M60.841 – M60.849, M60.851 – M60.859, M60.861 – M60.869, M60.871 – M60.88, M60.89, M60.9	Myopathy	G72.0, G72.2, G72.9	Rhabdomyolysis	M62.82	Cirrhosis	K70.30, K70.31, K71.7, K74.3 -K74.5, K74.60, K74.69, P78.81	ESRD	N18.5, N18.6, Z99.2
	Exclusions														
	Myalgia	M79.10 – M479.12, M79.18													
	Myositis	M60.80 – M60.819, M60.821 – M60.829, M60.831 – M60.839, M60.841 – M60.849, M60.851 – M60.859, M60.861 – M60.869, M60.871 – M60.88, M60.89, M60.9													
	Myopathy	G72.0, G72.2, G72.9													
	Rhabdomyolysis	M62.82													
	Cirrhosis	K70.30, K70.31, K71.7, K74.3 -K74.5, K74.60, K74.69, P78.81													
ESRD	N18.5, N18.6, Z99.2														
Statin Use in Patients with Diabetes (SUPD)	<table border="1"> <thead> <tr> <th colspan="2" data-bbox="506 1375 1513 1423">Exclusions</th> </tr> </thead> <tbody> <tr> <td data-bbox="506 1423 771 1465">Myopathy</td> <td data-bbox="771 1423 1513 1465">G72.0, G72.89, G72.9</td> </tr> <tr> <td data-bbox="506 1465 771 1507">Rhabdomyolysis</td> <td data-bbox="771 1465 1513 1507">M62.82</td> </tr> <tr> <td data-bbox="506 1507 771 1549">Cirrhosis</td> <td data-bbox="771 1507 1513 1549">K70.30, K70.31, K71.7, K74.3-5, K74.60, K74.69</td> </tr> <tr> <td data-bbox="506 1549 771 1598">ESRD</td> <td data-bbox="771 1549 1513 1598">N18.5, N18.6, N19, Z91.15, Z99.2</td> </tr> </tbody> </table>	Exclusions		Myopathy	G72.0, G72.89, G72.9	Rhabdomyolysis	M62.82	Cirrhosis	K70.30, K70.31, K71.7, K74.3-5, K74.60, K74.69	ESRD	N18.5, N18.6, N19, Z91.15, Z99.2				
	Exclusions														
	Myopathy	G72.0, G72.89, G72.9													
	Rhabdomyolysis	M62.82													
Cirrhosis	K70.30, K70.31, K71.7, K74.3-5, K74.60, K74.69														
ESRD	N18.5, N18.6, N19, Z91.15, Z99.2														
Medication Reconciliation Post-discharge (MRP)	<p>1111F – discharge medications reconciled with current medication list</p> <p>99483, 99495, 99496 – Transitional Care Management Services (TCM) includes medication reconciliation</p>														